Rheumatoid arthritis

Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies

Retrieved on: 
Thursday, December 1, 2022
Marketing, Nonunion, Regeneration, Certification, Patient, Annual report, Exosome, Rheumatoid arthritis, Research, Pharmaceutical industry, Dentistry

Novaxomx has obtained the exclusive rights to use Lysatpharmas patented exosome technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.

Key Points: 
  • Novaxomx has obtained the exclusive rights to use Lysatpharmas patented exosome technology for the research of optimizing biomimetic osteoconductive carrier materials by biologizing them with exosomes.
  • Novaxomx focuses on the research, development, certification, production, and marketing of disruptive, biosurgical therapies for use in musculoskeletal diseases and tissue regeneration.
  • Frank Plger, Chief Scientific Officer of Xlife Sciences AG and Managing Director of Lysatpharma GmbH, says: Xlife Sciences and curasan founded Novaxomx in March 2022.
  • Dr. Dirk Dembski, CEO of curasan AG, comments: The license Novaxomx has obtained from Lysatpharma allows Novaxomx to take an interdisciplinary approach to develop disruptive, biosurgical products that fundamentally improve bone healing.

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

Retrieved on: 
Wednesday, November 30, 2022
Growth, Adalimumab, Medicines and Healthcare products Regulatory Agency, MAA, Capsular contracture, Literature, Food, Health care, Compte rendu, Risk, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, Life, File, Inflammation, Rheumatoid arthritis, Drug development, Security (finance), MHRA, Behavior, Research, Investigational New Drug, Consultant, Medication, PALO, Hardness, FDA, HIV disease progression rates, Pharmaceutical industry

The MHRA reviewed the primary and secondary endpoints in the Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD) trial and the data provided by the Company.

Key Points: 
  • The MHRA reviewed the primary and secondary endpoints in the Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD) trial and the data provided by the Company.
  • The MHRA also asked for additional literature supporting the clinical safety of adalimumab from other approved indications such as rheumatoid arthritis.
  • However, there is no assurance that such a submission will be timely filed, or favorably received or approved.
  • About 180 Life Sciences Corp.
    180 Life Sciences Corp. is a clinical-stage biotechnology company driving ground-breaking studies into clinical programs which are seeking to address major unmet medical needs.

Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results

Retrieved on: 
Wednesday, November 30, 2022
Science, Cell, Rhinitis, Procurement, Therapy, NF-κB, NASAR, OTC, Option, Allergic rhinitis, Patient, Rheumatoid arthritis, Indian stock exchange, Sirna, ANCOVA, FDA, COVID-19, Allergen, RNA, Degenerative disease, Inflammation, Interim, Dose, Clinical trial, SAR, Safety, Drug discovery, Betahistine, Pharmacology, IND, KRAS, Nanoparticle, MD, Virus, Medical device, Pharmaceutical industry, Vaccine, Security (finance), Lithium, CHF, EU, Nuance

We continue to make good progress with the transformation of Altamira into an RNA delivery technology company, stated Thomas Meyer, Altamira Therapeutics founder, Chairman and CEO.

Key Points: 
  • We continue to make good progress with the transformation of Altamira into an RNA delivery technology company, stated Thomas Meyer, Altamira Therapeutics founder, Chairman and CEO.
  • Total operating expenses for the first half of 2022 were CHF 7.5 million compared with CHF 6.5 million for the first half of 2021.
  • R&D expenses for the first half of 2022 were CHF 3.6 million compared with CHF 3.4 million for the first half of 2021.
  • Altamira expects its total cash need for funding operations in 2022 to be in the range of CHF 12.0 to 13.0 million.

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Retrieved on: 
Tuesday, November 29, 2022
US Foods, Laboratory, Australian Securities Exchange, Chemistry, Vitiligo, Inflammatory bowel disease, Anxiety, Patient, Doctor of Philosophy, Incidence, Environment, Addiction, Immune system, Skin, Pain, Pigment, ASX, OSA, Rheumatoid arthritis, FDA, Concussion, Food, Genomics, Sleep apnea, Traumatic brain injury, TBI, Cannabinoid, Disease, Patent, American depositary receipt, CDMO, Atopic dermatitis, Safety, Dermatitis, Acquisition, Contract research organization, Pharmacology, COPD, CBG, Asthma, U.S. FDA, Psoriasis, Bronchitis, Pharmaceutical industry, Vaccine, Cannabigerol, Cannabidiol, Eurofins Scientific, MD

A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.

Key Points: 
  • A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.
  • In the study, ReneCann reduced disease scores in patients with each of the target skin diseases.
  • ReneCann also has the potential to be assessed for efficacy in other diseases where topical application may provide a benefit over conventional oral dosed cannabinoid formulations.
  • Incannex is investigating the use of Eurofins to develop and manufacture additional drug candidates acquired via the acquisition of APIRx Pharmaceuticals.

Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O

Retrieved on: 
Monday, November 28, 2022
Tobacco smoking, Opioid overdose, Cannabinoid, US Foods, United, CDC, Laboratory, Australian Securities Exchange, Chewing, CGMP, National Centre for Disease Control, CBD, Substance dependence, Inflammatory bowel disease, Anxiety, Fatal, Environment, Addiction, Pain, CB1, ASX, OSA, Rheumatoid arthritis, NDA, FDA, Cannabidiol, Concussion, Nicotine, Food, Genomics, Sleep apnea, Traumatic brain injury, TBI, Death, Patent, American depositary receipt, Opioid use disorder, CDMO, Safety, Acquisition, Contract research organization, Pharmacology, IND, COPD, Opioid, Nicotine gum, Asthma, U.S. FDA, Smoking, Bronchitis, Pharmaceutical industry, Tobacco, Eurofins Scientific

Eurofins will undertake formulation development and manufacture of CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O).

Key Points: 
  • Eurofins will undertake formulation development and manufacture of CannQuit Nicotine (CannQuit-N) and CannQuit Opioid (CannQuit-O).
  • Rapid onset and sustained effect are both qualities desirable for the treatment of addiction disorders.
  • Dr Mark Bleackley, chief scientific officer of Incannex, said: Opioid and nicotine addiction are significant health problems and a major burden on health systems throughout the world.
  • Incannex is investigating the use of Eurofins to develop and manufacture additional drug candidates acquired via the acquisition of APIRx Pharmaceuticals.

Neuromodulation Devices Markets, 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Medical Devices, Health, Neurology, Other Science, Science, Biotechnology, Webbed toes, Hypoglossal nerve, Hospital, Incidence, TENS, Neuromodulation, Gastroenterology, Degenerative disease, Pain management, SCS, Weaning, Stroke, Epilepsy, Chronic pain, Patient, Anxiety, Government, OSA, Ageing, Heart failure, Parkinson's disease, Transcutaneous electrical nerve stimulation, Obesity, Rheumatoid arthritis, CNS, Autoimmune disease, Central sleep apnea, Obstructive sleep apnea, Functional electrical stimulation, Diabetes, Mood disorder, Obsessive–compulsive disorder, Multiple sclerosis, Urinary incontinence, Urology, OCD, NMES, Movement disorders, Central nervous system, Investment, Pharmaceutical industry, Medical device, Beauty salon, Medicine, Dystonia, Depression, Gastroparesis

The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches.
  • Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices.
  • Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029.

Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company’s Phase 3 Trial in Rheumatoid Arthritis

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Clinical Trials, NYSE American, RA, History, Technetium-99m, Macrophage, Biopharmaceutical, Rheumatology, Health, Physician, Joint, Moderate, Drug Quality and Security Act, Annual report, Rheumatoid arthritis, Inflammation, Disease, NYSE, Risk, Research, Coronavirus, FDA, Pharmaceutical industry, Medical imaging, Patient

This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis (RA) patients switching to an anti-TNF therapy, addressing a large unmet medical need.

Key Points: 
  • This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis (RA) patients switching to an anti-TNF therapy, addressing a large unmet medical need.
  • These macrophage density changes may be observable weeks before disease modification can be detected with standard clinical assessments.
  • The NAV3-33 Phase 3 trial involves Tc99m tilmanocept imaging in participants with RA who are about to begin anti-TNF therapy.
  • Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis

Retrieved on: 
Wednesday, November 16, 2022
Marketing, Gesellschaft mit beschränkter Haftung, Patient, Medac, MTX, Rheumatoid arthritis, Senior, Gemeinschaft and Gesellschaft, Safety, Pharmaceutical industry, Eisai, Methotrexate

TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis.

Key Points: 
  • TOKYO, Nov 16, 2022 - (JCN Newswire) - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan with the indication of rheumatoid arthritis.
  • nippon medac obtained the manufacturing and marketing approval of Japan's first self-administrable subcutaneous injection formulation of MTX, a first line option for the treatment of rheumatoid arthritis, on September 26, 2022.
  • "Eisai has established a solid franchise and has extensive sales experience in the rheumatoid arthritis area in Japan.
  • It is also the first self-administrable MTX subcutaneous injection formulation for rheumatoid arthritis in Japan," said Hirohisa Iriyama, Representative Director and President of nippon medac.

EQS-News: Formycon Reports its Nine-month Figures for 2022

Retrieved on: 
Sunday, November 27, 2022
COVID-19, Marketing, Eye, Gesellschaft mit beschränkter Haftung, MedImmune, Inc. v. Genentech, Inc., EBITDA, Teva, Conditional sentence, Patient, ISIN, EBIT, Ophthalmology, Rheumatoid arthritis, Diabetes, Patent, International, HGB, Multiple sclerosis, Cancer, Sale, Press release, Research, Depreciation, Commercial code, FYB, Investment, Forecasting, Acquisition, Euro, Security (finance), Renewable energy, Fine chemical, EU

At the end of the third quarter, the Formycon Groups financial figures were expected as forecast.

Key Points: 
  • At the end of the third quarter, the Formycon Groups financial figures were expected as forecast.
  • Formycon is forecasting revenues at Group level of around Euro 40 million for the whole year.
  • The Formycon Group focuses on research and development for its own, or out-licensed biosimilars projects as well as its own COVID-19 drug (FYB207).
  • For the full year 2022, sales and earnings contributions from the marketing revenues in the additional territories are expected.

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Tuesday, November 22, 2022
Autoimmunity, Marketing, Bamlanivimab/etesevimab, Macular edema, EUA, Rheumatism, Severe acute respiratory syndrome coronavirus 2, NMPA, Junshi, B cell, Inflammatory bowel disease, Incidence, TNF, Prevalence, Microbiology, Patient, IBD, Rheumatoid arthritis, HKEX, Ulcerative colitis, Cataract, UC, FDA, Multifocal choroiditis and panuveitis, COVID-19, Adalimumab, SSE, Glaucoma, Cancer, Ankylosing spondylitis, Lilly, Inflammation, Retinopathy, Social responsibility, Severe cognitive impairment, Juvenile idiopathic arthritis, National Medical Products Administration, Degenerative disease, Macrophage, Bamlanivimab, Infection, Quality of life, Psoriasis, Uveitis, Pharmaceutical industry, Vaccine, Science, Chinese

is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.

Key Points: 
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).